GW Pharmaceuticals PLC GWPH, +2.62% said late Monday that it had a positive phase-three trial result for its Epidiolex drug. GW stock rose more than 7% in after-hours trading. Epidiolex is a drug that contains cannabidiol, or CBD, a compound found in cannabis plants. The drug is an anti-epilepsy medication and the phase-three trial was performed on 224 patients in six countries. GW said it was the fifth consecutive positive trial for Epidiolex. GW stock has gained 28% in the past year, as the S&P 500 index SPX, -0.45% rose 11%.
Have breaking news sent to your inbox. Subscribe to MarketWatch’s free Bulletin emails. Sign up here.
Thank you for reading this article! We’d love to hear your thoughts and answer your questions in the comments below.